ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Prognostic value of the CHAM score in non-small cell lung cancer patients treated with nivolumab.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Baseline Neutrophil-to-Lymphocyte Ratio and Two-Year Incident Distant Metastasis in Stage I-III Lung Cancer: A Single-Center Retrospective Cohort Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeReliable prognostic markers are needed to improve risk stratification in patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors. We evaluated the prognostic value of the CHAM score, a composite marker integrating systemic inflammation, hematologic parameters, and metastatic burden, in nivolumab-treated NSCLC patients. To our knowledge, its prognostic relevance in this setting has not been previously investigated.
methodsThis retrospective cohort study included 91 patients with histologically confirmed NSCLC who received nivolumab between 2020 and 2026. The CHAM score was derived from C-reactive protein, albumin, hemoglobin levels, and metastatic extent. Overall and progression-free survival were analyzed using the Kaplan-Meier method and compared with the log-rank test. Multivariable Cox proportional hazards regression evaluated the prognostic impact of the CHAM score, and receiver operating characteristic curve analysis determined the optimal cut-off.
resultsDuring follow-up, 59 deaths were observed. Patients with a CHAM score ≥ 4 had shorter overall survival than those with a CHAM score < 4, with median survival times of 6.7 and 18.7 months, respectively (log-rank p < 0.001). Progression-free survival was also reduced in the high-risk group, with median values of 2.6 versus 11.2 months (log-rank p < 0.001). In multivariable Cox regression analyses, a high CHAM score remained independently associated with worse overall and progression-free survival (p < 0.05 for both). Receiver operating characteristic analysis identified a CHAM score of 4 as the optimal cut-off.
conclusionsThe CHAM score may provide practical prognostic stratification in nivolumab-treated NSCLC patients; however, external validation is required.
Indexed as
Identifiers
42274904What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.